facebook
twitter
rss
account
search
search
 

FDA approves boxed warning for Exjade

Feb. 18, 2010 at 1:44 PM   |   Comments

WASHINGTON, Feb. 18 (UPI) -- The U.S. Food and Drug Administration says it has approved a boxed warning for Exjade, used to treat chronic iron overload due to blood transfusions.

The FDA said Exjade (deferasirox) is indicated for use in patients 2 years of age and older. The boxed warning will inform patients the drug might cause renal impairment, hepatic impairment and gastrointestinal hemorrhage. In some cases the reactions might be fatal.

The FDA said new language has also been added to the contraindications, warnings, precautions and drug interactions sections of the prescribing information for healthcare professionals.

Exjade is marketed by Novartis Oncology, part of the Novartis Pharmaceuticals Corp.

© 2010 United Press International, Inc. All Rights Reserved. Any reproduction, republication, redistribution and/or modification of any UPI content is expressly prohibited without UPI's prior written consent.
Most Popular
1
SpaceX Dragon returns safely from ISS, splashes into Pacfic Ocean SpaceX Dragon returns safely from ISS, splashes into Pacfic Ocean
2
Google exec breaks skydive record with dive from near-space Google exec breaks skydive record with dive from near-space
3
Powerful new microscope sees cell division in real time Powerful new microscope sees cell division in real time
4
Stone tools reveal Ice Age settlement in the Andes Stone tools reveal Ice Age settlement in the Andes
5
Coal-rich Poland wants concessions in EU climate deal Coal-rich Poland wants concessions in EU climate deal
Trending News
Around the Web
x
Feedback